185 related articles for article (PubMed ID: 23271781)
1. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
[TBL] [Abstract][Full Text] [Related]
2. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
3. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
4. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
7. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
Wilt TJ; Ullman KE; Linskens EJ; MacDonald R; Brasure M; Ester E; Nelson VA; Saha J; Sultan S; Dahm P
J Urol; 2021 Apr; 205(4):967-976. PubMed ID: 33350857
[TBL] [Abstract][Full Text] [Related]
10. The potential impact of comparative effectiveness research on U.S. health care expenditures.
Perlroth DJ; Goldman DP; Garber AM
Demography; 2010; 47 Suppl(Suppl 1):S173-90. PubMed ID: 21302424
[TBL] [Abstract][Full Text] [Related]
11. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
12. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
13. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.
Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Asner I; Xie L; Meadows E; Danella J
J Med Econ; 2017 Aug; 20(8):825-831. PubMed ID: 28534659
[TBL] [Abstract][Full Text] [Related]
15. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy.
Goharderakhshan RZ; Grossfeld GD; Kassis A; Shinohara K; Roach M; Carroll PR
Urology; 2000 Oct; 56(4):622-6. PubMed ID: 11018618
[TBL] [Abstract][Full Text] [Related]
16. Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer.
Gustavsen G; Taylor K; Cole D; Gullet L; Lewine N
Future Oncol; 2020 Dec; 16(36):3061-3074. PubMed ID: 32902306
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
18. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies.
Muralidhar V; Nguyen PL
Urol Oncol; 2017 Feb; 35(2):76-85. PubMed ID: 27473636
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
20. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.
Daly T
World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]